肾康灵颗粒治疗早期高血压肾病的临床效果及对患者mAlb和Cys-C指标影响观察

Clinical effect of Shenkangling Granule on early hypertensive nephropathy and its effect observation on mAlb and Cys-C indexes

目的分析肾康灵颗粒治疗早期高血压肾病的临床效果及对患者尿微量白蛋白(mAlb)和血清胱抑素C(Cys-C)指标的影响。方法 82例早期高血压肾病患者,随机分为参照组和实验组,各41例。参照组患者给予常规西医治疗,实验组患者在参照组基础上给予肾康灵颗粒治疗,比较两组患者治疗效果、治疗前后Cys-C、mAlb指标变化情况。结果实验组治疗总有效率为92.68%,明显高于参照组的73.17%,差异有统计学意义(P<0.05)。治疗前,两组患者Cys-C、mAlb指标比较,差异无统计学意义(P>0.05);治疗后,实验组Cys-C、mAlb指标分别为(1.0±0.3)mg/L、(74.2±7.0)mg/L,参照组Cys-C、mAlb指标分别为(1.3±0.2)mg/L、(86.1±8.2)mg/L,比较差异有统计学意义(P<0.05)。结论早期高血压肾病患者给予肾康灵颗粒治疗能有效缓解患者临床症状,减轻肾功能损伤,值得临床应用。

Objective To analyze the clinical effect of Shenkangling Granule on patients with early hypertensive nephropathy and its effect on urinary microalbumin （mAlb） and Cystatin C （Cys-C） indexes. Methods A total of 82 patients with early hypertensive nephropathy were randomly divided into reference group and experimental group, 41 cases in each group. Patients in the control group were treated with conventional western medicine, patients in the experimental group were treated with Shenkangling Granule on the basis of the control group. The curative effect, the changes of Cys-C and mAlb indexes before and after treatment between the two groups were compared. Results The total effective rate of the experimental group was 92.68%, which was significantly higher than 73.17% of the control group, the difference was statistically significant （P〈0.05）. Before treatment, there were no significant differences in the Cys-C and mAlb indexes between the two groups （P〉0.05）. After treatment, the Cys-C and mAlb indexes of the experimental group were （1.0±0.3） mg/L and （74.2±7.0） mg/L respectively, which were significantly lower than （1.3±0.2） mg/L and （86.1±8.2） mg/L of the reference group, the differences were statistically significant （P〈0.05）. Conclusion The treatment of Shenkangling Granule for patients with early hypertensive nephropathy can effectively relieve the clinical symptoms and alleviate renal function damage, it is worthy of clinical application.